Emergent BioSolutions Secures Over $60M in New U.S. and International Government Contracts for Smallpox Countermeasures
EBS has more than doubled off its 52-week low of $4.02.
Summary
Emergent BioSolutions has secured over $60 million in new contracts for its smallpox medical countermeasures. This includes a $54 million contract with the U.S. Department of Health and Human Services (ASPR) for Vaccinia Immune Globulin Intravenous (VIGIV) and $6.6 million in new orders from an international government partner for ACAM2000 smallpox vaccine. These significant awards, totaling $60.6 million, represent a material revenue stream for the company, given its market capitalization. The news reinforces Emergent's role in global biodefense preparedness and is a positive development for its products business. This information is new and not reflected in the recent SEC filings regarding a proxy statement.
At the time of this announcement, EBS was trading at $8.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $425M. The 52-week trading range was $4.02 to $14.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.